PTM Biosciences is dedicated to advancing personalized medicine by developing proteomics-based products and tools for disease diagnosis, disease management, and drug development.
The company is developing and commercializing a technology called Post Translational Modifications Profiling, conceived at the Harvard Medical School by Dr. Yifat Merbl, a co-founder of the company. This proprietary technology uncovers the potential of protein modifications to reveal the actual physiological state of a disease and provides key information for the identification of novel drug targets, elucidation of mechanism of action of drugs, and discovery of predictive biomarkers.
By measuring PTM activity from clinical samples such as blood or tumor tissue, the company generates a patient-specific, activity-based signature as a core facilitator of personalized medicine.
Future developments in the company's pipeline include applying its PTM profiling platform for the analysis of liquid biopsies of melanoma and SLE patients and generating diagnostic biomarkers that can detect, predict, and monitor disease activity of these patients in order to serve as the basis for the development of novel treatments.